Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04285320
Other study ID # 1565199
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date March 2021
Est. completion date April 2023

Study information

Verified date January 2021
Source Atlantic Health System
Contact Caroline Sabatino, MPH
Phone 973-971-7361
Email caroline.sabatino@atlantichealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a research study that aims to determine if antibiotic bladder instillations (placing an antibiotic directly into the bladder) over several sessions at the office is a good option to prevent recurrent urinary tract infections, in comparison with oral suppression therapy (taking daily antibiotics in the form of pills by mouth). Oral antibiotic suppression therapy is currently the most common treatment route for recurrent urinary tract infections in post-menopausal women. The bladder antibiotic instillation may overcome the disadvantages of oral suppression therapy such as antibiotic resistance, certain side effects, and recurrence of infections after finishing the treatment course.


Description:

In this study, the investigators aim to determine the effectiveness of intra-vesical antibiotic instillations for the prophylactic treatment of recurrent urinary tract infections in menopausal women in comparison with oral suppressive therapy. This is a parallel un-blinded randomized-controlled trial. the investigators will randomize post-menopausal women with recurrent urinary tract infections to either receive 6-8 intra-vesical antibiotic instillations at the office or to receive 3 months of oral antibiotic suppressive therapy. In the bladder instillation arm, based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol: - Amikacin-30 mg in 60 ml of sterile water - Gentamycin-80mg in 60ml sterile water - Tobramycin-80 mg in 100 ml of sterile water In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile: - Trimethoprim daily (100 mg) - Trimethoprim/sulfamethoxazole daily (40 mg/200 mg) - Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg) - Nitrofurantoin monohydrate/macrocrystals daily (50 mg) - Nitrofurantoin monohydrate/macrocrystals daily (100 mg) - Cephalexin daily (125 mg) - Cephalexin daily (250 mg) - Fosfomycin every 10 days (3 grams) All medications used in this study are approved by the FDA to treat urinary tract infections. Participants will be followed for total of 3 months after finishing either treatment course by only reviewing their medical records to collect data regarding development of urinary tract infections after treatment. Primary endpoint/outcome: • To compare the number of women developing urinary tract infections during the 3 months following treatment between the two groups. Secondary endpoints/outcomes: - To compare the rate of antibiotic resistance of isolated pathogens after intravesical antibiotic instillation vs. oral antibiotic suppressive therapy - To compare side effects of the two treatment modalities


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date April 2023
Est. primary completion date April 2023
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - Post-menopausal women with recurrent urinary tract infections (2 infections in a 6-month period or at least 3 infections in a 1-year period) - Receiving estrogen vaginal therapy for 1 month prior to enrollment - Able to come in to the office twice weekly for 3-4 weeks - English speaking - No allergy to at least one of the three antibiotics used for bladder instillations and at least one of the four antibiotics recommended for oral suppressive therapy. - No uro-pathogen resistance to at least one of the three antibiotics used for bladder instillations and at least one of the four antibiotics recommended for oral suppressive therapy. Exclusion Criteria: - Allergy to all study antibiotics (Gentamicin, Tobramycin, Amikacin, Trimethoprim/sulfamethoxazole, Fosfomycin, Nitrofurantoin and Cephalexin) - Recent Urine culture with pathogens resistant to all study antibiotics (Gentamicin, Tobramycin, Amikacin, Trimethoprim/sulfamethoxazole, Fosfomycin, Nitrofurantoin and Cephalexin) - Renal failure (Creatinine clearance <30ml/min) - History of urinary retention - History of genitourinary structural abnormalities

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Intravesical antibiotic instillation
Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol: Amikacin-30 mg in 60 ml of sterile water Gentamycin-80mg in 60ml sterile water Tobramycin-80 mg in 100 ml of sterile water
Antibiotic oral suppressive therapy
In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile: Trimethoprim daily (100 mg) Trimethoprim/sulfamethoxazole daily (40 mg/200 mg) Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg) Nitrofurantoin monohydrate/macrocrystals daily (50 mg) Nitrofurantoin monohydrate/macrocrystals daily (100 mg) Cephalexin daily (125 mg) Cephalexin daily (250 mg) Fosfomycin every 10 days (3 grams)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Atlantic Health System

References & Publications (1)

Chernyak S, Salamon C. Intravesical Antibiotic Administration in the Treatment of Recurrent Urinary Tract Infections: Promising Results From a Case Series. Female Pelvic Med Reconstr Surg. 2020 Feb;26(2):152-154. doi: 10.1097/SPV.0000000000000810. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The percentage of participants with urinary tract infections following treatment course To compare the percentage of women developing urinary tract infections during the 3 months following treatment between the two groups. Assessed starting immediately after the treatment is completed for a total of 3 months.
Secondary The rate of antibiotic resistance of pathogens in participants developing urinary tract infections after completing the treatment course. To compare the rate of antibiotic resistance of isolated pathogens when participants develop a urinary tract infection during the 3 months follow up period after intra-vesical antibiotic instillation vs. oral antibiotic suppressive therapy. the percentage of antibiotics on the susceptibility list of urine cultures will be compared between participants developing urinary tract infection in each group during the 3 months follow-up period after completing the treatment. Assessed starting immediately after the treatment is completed for a total of 3 months
Secondary the percentage of patients developing side effects of the 2 treatments To compare the percentage of patients developing side effects between the two treatment modalities. At their routine follow up visits patients will be asked about whether or not they developed side effects and the type and severity of side effects of the treatment received. The percentage of patients developing side effects (per type and severity) in each arm will be compared. From the date of randomization until the date of first documented side effect assessed up to 3 months after the treatment is completed in each arm
See also
  Status Clinical Trial Phase
Completed NCT02357758 - Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Phase 4
Completed NCT04306731 - Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections. N/A
Recruiting NCT05553652 - The Effect of ASTARTE™ on Recurrent Urinary Tract Infection N/A
Completed NCT01958073 - Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women Phase 4
Recruiting NCT05652374 - Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study Phase 4
Recruiting NCT06124820 - RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women With Recurrent Urinary Tract Infections N/A
Recruiting NCT04807894 - Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo Phase 4
Enrolling by invitation NCT04077580 - The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI Phase 4
Terminated NCT03143920 - Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder Early Phase 1
Recruiting NCT04859621 - Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections Phase 2
Terminated NCT04831840 - Recurrent Urinary Tract Infections and the Microbiome
Withdrawn NCT03854396 - Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women Phase 3
Completed NCT02705495 - Acupuncture for Prevention of Recurrent Urinary Tract Infections. N/A
Active, not recruiting NCT05537519 - Phage Therapy for the Treatment of Urinary Tract Infection Phase 1/Phase 2
Recruiting NCT06035601 - EHR-integrated rUTI Texting Platform N/A
Recruiting NCT03142295 - Controlled Human Urine Transfusion for UTI N/A
Recruiting NCT05895578 - Effect of a Probiotic on the Urinary Tract Microbiota of Participants With Recurrent Urinary Tract Infection. N/A
Completed NCT00214045 - Rigid Versus Flexible Cystoscopy in Women N/A
Enrolling by invitation NCT05551949 - Preventing Recurrent UTI With Vaginal Estrogen Phase 4
Recruiting NCT05472779 - Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections Phase 2